izpis_h1_title_alt

Volumetric absorptive microsampling for the therapeutic drug monitoring of psychiatric patients treated with cariprazine
ID Millán-Santiago, Jaime (Avtor), ID Vitagliano, Rosalba (Avtor), ID Mondella, Fortunata (Avtor), ID Mandrioli, Roberto (Avtor), ID Sardella, Roccaldo (Avtor), ID Vovk, Tomaž (Avtor), ID Lucena, Rafael (Avtor), ID Cárdenas, Soledad (Avtor), ID Boaron, Federico (Avtor), ID Mercolini, Laura (Avtor)

.pdfPDF - Predstavitvena datoteka, prenos (1,55 MB)
MD5: 748AC46A004ED5CBE78F04E7DA1202BE
URLURL - Izvorni URL, za dostop obiščite https://www.sciencedirect.com/science/article/pii/S0731708523005095 Povezava se odpre v novem oknu

Izvleček
Psychiatric disorders are usually treated with antipsychotic agents belonging to different pharmacological and chemical classes, the most recent ones collectively known as “third-generation antipsychotics”, such as cariprazine, approved in 2015 for the treatment of patients affected by schizophrenia. For these patients, a frequent therapeutic drug monitoring (TDM) becomes essential to assess compliance and to optimise and personalise their therapy, also due to cariprazine interindividual variability and narrow therapeutic range. In this study, a bioanalytical method featuring miniaturised sampling and pretreatment was developed, based on volumetric absorptive microsampling (VAMS) for TDM of psychiatric patients under cariprazine treatment and compared to a classic, reference method based on fluid plasma analysis. Minimally invasive whole blood VAMS was coupled to an original instrumental method based on ultra-high performance liquid chromatography hyphenated to mass spectrometry (UHPLC-MS). A feasible and streamlined, yet reliable VAMS pretreatment protocol was carefully optimised and the VAMS-UHPLC-MS methodology was validated with satisfactory results in terms of linearity ($r^2$ > 0.9970 in the 1.5-100 ng/mL range), precision (%RSD ≤ 11.7), extraction yield (> 90.0%) and matrix effect (8.2≤ RE% ≤ 10.9%). Finally, the microsampling approach coupled to UHPLC-MS was successfully applied to the TDM of psychiatric patients treated with cariprazine and compared with standard fluid plasma analysis, providing reliable quali-quantitative results, and proving to be readily applicable to the clinical practice in TDM programs as a useful alternative to cariprazine plasma analysis. This is the first report of a successful microsampling application, and in particular the first report of VAMS application, for the TDM of cariprazine.

Jezik:Angleški jezik
Ključne besede:cariprazine, microsampling, therapeutic drug monitoring (TDM), volumetric absorptive microsampling (VAMS), microsampling (VAMS)
Vrsta gradiva:Članek v reviji
Tipologija:1.01 - Izvirni znanstveni članek
Organizacija:FFA - Fakulteta za farmacijo
Status publikacije:Objavljeno
Različica publikacije:Objavljena publikacija
Leto izida:2023
Št. strani:Str. 1-7
Številčenje:Vol. 236, art. 115740
PID:20.500.12556/RUL-151577 Povezava se odpre v novem oknu
UDK:615.214:616.89
ISSN pri članku:0731-7085
DOI:10.1016/j.jpba.2023.115740 Povezava se odpre v novem oknu
COBISS.SI-ID:165592835 Povezava se odpre v novem oknu
Datum objave v RUL:10.10.2023
Število ogledov:412
Število prenosov:15
Metapodatki:XML RDF-CHPDL DC-XML DC-RDF
:
Kopiraj citat
Objavi na:Bookmark and Share

Gradivo je del revije

Naslov:Journal of pharmaceutical and biomedical analysis
Skrajšan naslov:J. pharm. biomed. anal.
Založnik:Elsevier B.V.
ISSN:0731-7085
COBISS.SI-ID:6557447 Povezava se odpre v novem oknu

Licence

Licenca:CC BY-NC-ND 4.0, Creative Commons Priznanje avtorstva-Nekomercialno-Brez predelav 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by-nc-nd/4.0/deed.sl
Opis:Najbolj omejujoča licenca Creative Commons. Uporabniki lahko prenesejo in delijo delo v nekomercialne namene in ga ne smejo uporabiti za nobene druge namene.

Sekundarni jezik

Jezik:Slovenski jezik
Ključne besede:kariprazin, mikrovzorčenje, terapevtsko spremljanje zdravil, volumetrično absorpcijsko mikrovzorčenje, antipsihotiki, psihiatrija

Projekti

Financer:Drugi - Drug financer ali več financerjev
Program financ.:Spanish Ministry of Science and Innovation
Številka projekta:PID2020-112862RB-I00

Financer:Drugi - Drug financer ali več financerjev
Program financ.:Spanish Ministry of Science, Innovation and Universities
Številka projekta:FPU19/01488

Podobna dela

Podobna dela v RUL:
Podobna dela v drugih slovenskih zbirkah:

Nazaj